

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Incorporated in the People's Republic of China)
(Company Registration No.: 91120000103100784F)

RESOLUTIONS PASSED AT THE 9TH BOARD MEETING FOR FY2026

The board of directors (the “Board”) and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the “Company”) hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

On 29 October 2026, the Company duly convened its 9th Board meeting for the financial year ending 31 December 2026 (“FY2026”) via a combination of a physical meeting and teleconference. The meeting was held in compliance with the applicable Company Law and Securities Law, as well as the Articles of Association of the Company. The following resolutions were duly passed at the meeting:

1. That the third quarter financial report of the Company for FY2026 prepared in accordance with the accounting standards of the People's Republic of China, and the third quarter interim financial report of the Company for FY2026 prepared in accordance with the International Financial Reporting Standards, be approved.

To the best of the knowledge of the Directors and management of the Company, there is no other information that would cause the contents of the aforesaid reports to be false or misleading.

The above matter has been considered and approved by the Audit Committee.

Please refer to the Company's separate announcement on its financial results for the third quarter of FY2026 released on the same date as this announcement for further details.

2. That the proposed entry by the Company, through its Health Technology Industry Development Branch (健康科技产业发展分公司), into a new media promotion services agreement (新媒体宣传服务协议) with Zhongjian Haoda Medical Supply Chain Management Service (Tianjin) Co., Ltd. (众健浩达医疗供应链管理服务 (天津) 有限公司), which constitutes an interested person transaction, be approved.

Mr. Guo Min, Ms. Wang Lei, Mr. Xing Jianhua and Ms. Mao Weiwen, each being an interested director, abstained from voting on this resolution.

The above matter has been considered and approved at the 4th Special Meeting of the Independent Directors of the Company for FY2026.

Please refer to the Company's separate announcement entitled “*The Proposed Entry into a New Media Promotion Services Agreement as an Interested Person Transaction*” released on the same date as this announcement for further details.

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
30 October 2026